Centre Testing Intl Group (300012) Report Interpretation

Overview

This earnings review assesses Centre Testing's 1H26 and 2Q26 performance and argues that the more important development is improving growth quality rather than faster reported revenue alone. Goldman Sachs maintains Buy after lifting earnings estimates and its target price.

Core views

Centre Testing reported 1H26 revenue, EBIT and net profit of Rmb3,429mn, Rmb598mn and Rmb564mn, up 16%, 24% and 21% year on year and in line with its pre-announcement. Implied 2Q26 revenue, EBIT and net profit were Rmb1,935mn, Rmb424mn and Rmb385mn, up 16%, 19% and 16%, respectively; these were -1%, +8% and +1% versus Goldman Sachs estimates. Operating cash flow improved to Rmb438mn, up 150% year on year. Management attributed roughly 6 percentage points of 1H26 revenue growth to M&A consolidation and roughly 10 percentage points to organic growth, consistent with its preference for organic growth to remain the larger contributor. The report's central conclusion is that growth is shifting toward businesses with better operating leverage and cash conversion. Medical testing moved into a profitability inflection: segment revenue grew 57% in 1H26 and 58% in 2Q26, while 1H26 gross margin rose 9.1 percentage points year on year. Management said the segment was profitable for May through July after losses in the first four months; strong CRO orders, capacity near saturation, and an approved roughly Rmb100mn Kunshan Phase II investment support the outlook. Consumer Goods grew fully organically, with 1H26/2Q26 revenue up 13%/11% and 1H26 gross margin up 5.4 percentage points. Export-related categories and automotive testing supported demand, while semiconductor testing-services revenue grew strongly as lower-margin hardware and socket revenue declined or was deferred, reducing losses despite limited reported semiconductor revenue growth. Margins in Life Science, Industrial Products and International Trade faced modest pressure, but Goldman Sachs views this mainly as mix and timing rather than deterioration in underlying operations. Life Science 1H26 gross margin fell 1.3 percentage points as lower-margin acquired food assets diluted the mix, although environmental testing efficiency improved. Industrial Products' 1H26 gross margin fell 1.5 percentage points, with SafetySA and Emicert carrying lower margins and maritime disruption affecting shipping activity; organic industrial growth was only about 5-6% as the company exited low-quality construction work. International Trade remained structurally high margin, but its 1H26 gross margin declined 1.6 percentage points because lower-margin audit and inspection grew faster than chemical and reliability testing. The report expects medical and consumer testing to drive full-year gross-margin improvement, while M&A asset margin improvement is a multi-period process. Management is prioritizing project selectivity, collections and productive capacity over headline revenue and property-heavy expansion. Capex is expected to return toward 10% of revenue from 7%, excluding base construction, directed at semiconductors, medical, medical devices, NEV/autonomous driving, low-altitude economy and robotics. Overseas revenue exceeded 10% of group sales after 63% growth in 1H26, supported by integration of SafetySA, Emicert and Openview and by Ugene's Singapore food-testing platform. Goldman Sachs notes that the company targets higher-value industrial niches and international certification opportunities, while AI has progressed to more than 120 application scenarios focused initially on efficiency, customer service, opportunity capture and analytical accuracy. Goldman Sachs makes only about a 1% adjustment to 2026E-30E revenue but raises net-income estimates by roughly 3-5%, reflecting the medical profit inflection, consumer-margin expansion, semiconductor loss reduction and better operating and cash-flow discipline despite near-term acquisition mix dilution. It raises the 12-month target price to Rmb18.60 from Rmb17.70, based on 21x 2027E P/E, and maintains Buy. Its longer-term case assumes China's TIC market grows at a 7% CAGR and forecasts Centre Testing's 2026-30E revenue and net-profit CAGR at 12% and 16%.

Analysis framework

Goldman Sachs starts with reported earnings versus its estimates, then decomposes growth between organic expansion and acquired revenue. It evaluates revenue mix, segment-level growth and gross margins to distinguish structural operating improvement from acquisition, category-mix and timing effects. It then links cash flow, capex, overseas integration and capacity additions to earnings forecasts and values the shares on 2027E P/E.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Forward P/E valuation

  The target price of Rmb18.60 is based on a 21x multiple of projected 2027 earnings.

• Industry AnalysisVolume-price decomposition

  Growth-quality and segment-mix analysis

  The report separates organic and M&A-led growth and examines how segment and service mix affects revenue, margins and profit conversion.

• Corporate Fundamentals and FinanceFree cash flow analysis

  Operating cash-flow and capital-allocation analysis

  The report uses the 150% year-on-year increase in operating cash flow and the planned capex mix to assess revenue quality, collections and investment discipline.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Centre Testing Intl Group (300012.SZ)

  Primary covered company; the report expects higher-quality mix, margin resilience and improved profitability to support earnings upgrades.

  Strengths

  Organic growth remains the larger growth contributor; medical profitability is improving, consumer margins are expanding, and operating cash flow rose sharply.

  Weaknesses

  Reported growth and margins in some segments are diluted by lower-margin acquired assets, mix effects and timing.

  Comparison

  Goldman Sachs views operational performance as more resilient than comparable peers, citing market-share gains and consistent margins.

  Risks

  Credibility damage, pricing competition, receivables exposure from the 3rd National Soil Census and acquisition-related impairment.

Key data

• 1H26 revenueRmb3,429mn+16% year on year
• 1H26 EBIT / net profitRmb598mn / Rmb564mn+24% / +21% year on year
• 2Q26 revenue / EBIT / net profitRmb1,935mn / Rmb424mn / Rmb385mn+16% / +19% / +16% year on year
• 1H26 operating cash flowRmb438mn+150% year on year
• Overseas revenue growth+63% year on year in 1H26Overseas revenue exceeded 10% of group sales
• 2026E-30E net-income revision+3-5%Revenue estimates changed by about 1%
• Target priceRmb18.60Raised from Rmb17.70; based on 21x 2027E P/E

Impact & implications

The report argues that the company is becoming less dependent on lower-quality revenue and more exposed to medical, consumer, testing-service and higher-value certification opportunities. This mix shift, together with stronger cash conversion and selective capacity investment, underpins Goldman Sachs' higher earnings estimates and maintained Buy rating.

Risks

• Damage to the company's credibility could weaken the investment case.
• Intensifying pricing competition could pressure profitability.
• Accounts-receivable risk related to the 3rd National Soil Census could affect cash collection.
• Acquisitive growth could result in impairment.

What to watch

• Whether medical and consumer testing deliver the expected full-year gross-margin uplift.
• The pace of semiconductor testing-service scaling and the timing of segment breakeven.
• Margin improvement at SafetySA and Emicert as integration progresses.
• Overseas revenue mix and integration progress for SafetySA, Emicert, Openview and Ugene.
• Capex discipline and the shift toward productive laboratory capacity rather than base construction.